We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Assay Detects Acute Scrub Typhus

By LabMedica International staff writers
Posted on 16 Oct 2011
A molecular assay has been developed and evaluated in a clinical setting for the diagnosis of endemic scrub typhus.

A loop-mediated isothermal polymerase chain reaction (PCR) assay (LAMP) has been tested for the diagnosis of acute scrub typhus in low-resource, primary health care settings to guide clinical therapy.

A prospective fever study, including 161 patients from scrub typhus-endemic was carried out in Chiang Rai, northern Thailand by scientists at the Mahidol University (Bangkok, Thailand). More...
The scrub typhus infection criteria was a positive cell culture isolate; an admission immunoglobulin (Ig) M titer equal or greater than 1:12,800 using the “gold standard” indirect immunofluorescence assay (IFA); a four-fold rising IFA IgM titer and/or a positive result in at least two out of three PCR assays.

The molecular assays were a nested 56 kDa PCR, a 47 kDa real time PCR assay, a highly sensitive PCR primer set based on the GroEl gene, and the LAMP test. The LAMP test was performed using the Loopamp kit (Eiken Chemical Co. Ltd., Tokyo, Japan). All PCR assays, the including LAMP demonstrated high specificity ranging from 96% to 99%, with sensitivities varying from 40% to 56%, similar to the antibody based rapid test, which had a sensitivity of 47% and a specificity of 95%. After two days of fever the results of the admission assays were as follows: LAMP assay had a positivity rate of 25%, higher than that of the GroEl and 47 kD real-time assays which were both at 17%, and the immunochromatographic test (PanBio; Brisbane, Australia) was lowest with 8%.

The authors concluded that the diagnostic accuracy of the LAMP assay for scrub typhus was similar to real-time and nested conventional PCR assays, but superior to the antibody-based rapid test in the early disease course. This is where the new LAMP methodology has potential as it is inexpensive, simple to perform and requires only a water bath or simple heating block instead of a thermocycler. The combination of DNA- and antibody-based detection methods increased sensitivity with minimal reduction of specificity, and expanded the timeframe of adequate diagnostic coverage throughout the acute phase of scrub typhus. This disease is caused by the rickettsial organism Orientia tsutsugamushi and transmitted by mites. The study was published in the September 2011 issue of the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
Mahidol University
Eiken Chemical Co. Ltd.
PanBio


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.